Novartis AG

NYSE:NVS

Drug Manufacturers - General

Healthcare
$155.21 -2.24%

-$3.38 today

Market cap
$293.13B
Beta
0.49
P/E (TTM)
20.7
EPS (TTM)
$7.06
Dividend yield
3.13%
52W Low $112.34High $170.46

Volume 2.75M

Average 1.56M

NVS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Novartis AGNYSE: NVS

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares declines year over year

Q2 FY2026 weighted avg shares of 1.91B shares fell 2.2% year over year, ahead of the -3.3% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 0.2% from the prior quarter. Over 3 fiscal years it compounded at -3.8% a year.

Context

  • Weighted avg shares increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -2.2% holds above the trailing-twelve-month pace of -3.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
1.91B-0.2% QoQ
Last fiscal yearDec 2025
1.94B-3.9% YoY
LTMJun 2026
1.91B-3.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.2%——
1 year-3.9%——
3-year CAGR-3.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
1.94B USD
Year-over-year change
-3.9%
4-year CAGR
-3.6%

Weighted Avg Shares vs competitors

How NVS compares with its peers on the latest reported figures

  • NVS's LTM Jun 2026 weighted avg shares of 1.91B shares is the 8th highest of the 11 companies compared; the peer median is 2.23B shares.
  • Its year-over-year change of -3.3% is the lowest of 11, against a peer median of -0.2%.
  • Over three fiscal years its annual growth of -3.8% compares with a peer median of -0.3%.
NVS Competitors Peer median
Weighted Avg Shares for NVS and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.69B +0.3%+0.4%
NVONovo Nordisk A/SLTM Jun 20264.44B -0.2%-0.6%
MRKMerck & Co., Inc.LTM Jun 20262.48B -2.0%-0.4%
JNJJohnson & JohnsonLTM Sep 20262.44B +1.0%-2.4%
SNYSanofiLTM Jun 20262.42B -2.7%-0.8%
BMYBristol-Myers Squibb CompanyLTM Jun 20262.04B +0.5%-1.4%
GSKGSK plcLTM Jun 20262.01B -1.4%+0.2%
NVSNovartis AGLTM Jun 20261.91B -3.3%-3.8%
ABBVAbbVie Inc.LTM Sep 20261.77B +0.1%+0.1%
AZNAstraZeneca PLCLTM Sep 20261.55B -0.2%+0.0%
GILDGilead Sciences, Inc.LTM Jun 20261.24B -0.3%-0.3%
Peer median (excluding NVS) 2.23B-0.2%-0.3%

Competitors are the stored peer set for NVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.97B43.46B46.66B51.72B54.81B
Cost of Revenue11.74B11.58B12.47B12.83B13.69B
Gross Profit32.24B31.88B34.19B38.9B41.12B
Gross Margin73.3%73.4%73.3%75.2%75.0%
Research & Development8.64B9.17B11.37B10.02B10.74B
Selling, General & Admin12.83B12.19B12.52B12.57B13.31B
Operating Expenses22.18B23.93B24.42B24.35B24.05B
Depreciation & Amortization5.6B6.71B8.28B6.07B5.35B
EBITDA30.91B14.68B18.26B20.72B22.99B
EBITDA Margin70.3%33.8%39.1%40.1%41.9%
Operating Income10.06B7.95B9.77B14.54B17.07B
Operating Margin22.9%18.3%20.9%28.1%31.2%
Interest Income71M377.74M629.24M567.68M374.91M
Interest Expense905M834.62M876.12M1.04B1.19B
Other Income / Expenses14.47B(769M)(646M)(904M)(638.25M)
Income Before Tax24.53B7.18B9.12B13.64B16.44B
Pre-Tax Margin55.8%16.5%19.6%26.4%30.0%
Income Tax Expense1.63B1.13B551M1.7B2.4B
Net Income24.02B6.96B14.85B11.94B14.06B
Net Margin54.6%16.0%31.8%23.1%25.6%
EPS (Basic)10.713.197.155.927.25
EPS (Diluted)10.633.177.105.877.19
Weighted Avg Shares2.24B2.18B2.08B2.02B1.94B
Weighted Avg Shares (Diluted)2.26B2.2B2.09B2.04B1.96B

Novartis AG

NYSE:NVS

Intrinsic Alpha fair value

Locked

Current Price

$155.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.